Literature DB >> 14611115

Increased serum levels of interleukin-15 in rheumatoid arthritis with long- term disease.

I Gonzalez-Alvaro1, A M Ortiz, R Garcia-Vicuña, A Balsa, D Pascual-Salcedo, A Laffon.   

Abstract

OBJECTIVE: To study the serum levels of IL-15 in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), seronegative spondyloarthropathies (SSd) and healthy donors.
METHODS: The IL-15 serum levels were measured by ELISA in sera from 50 RA patients, 30 patients with SLE, 30 patients with SSd and 30 healthy donors. In RA patients, several clinical and demographic parameters were also obtained at the time of sample collection. IL-15 levels were compared in different RA subpopulations (positive or negative rheumatoid factor [RF], long term or recent onset disease, high or low disease activity). In addition, the possible association with other demographic and clinical parameters (gender, age, disease duration, etc) was also analysed.
RESULTS: RA patients had significantly higher serum levels of IL-15 (102.4 +/- 150 pg/ml; p = 0.0001) than SLE patients (9.8 +/- 15.3 pg/ml), SSd patients (7.9 +/- 14.6 pg/ml) and healthy donors' (5.2 +/- 11.6 pg/ml). RA patients with a disease evolution less than 2 years showed lower IL-15 levels (33.7 +/- 62.2 pg/ml) than those with long-term disease (152.4 +/- 64.6 pg/ml; p = 0.004). In addition, a significant correlation between IL15 in serum and the number of disease-modifying antirheumatic drugs (DMARDs) prescribed was detected in RA patients (r = 0.42; p = 0.002). No association between IL-15 levels and age, gender, RF or disease activity was observed in this group.
CONCLUSION: IL-15 is elevated in RA patients, specially in those with long term disease, compared to other rheumatic disorders. This finding supports that IL-15 is involved in the perpetuation of RA synovitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14611115

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  20 in total

Review 1.  A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis.

Authors:  Brian Astry; Erin Harberts; Kamal D Moudgil
Journal:  J Interferon Cytokine Res       Date:  2011-12       Impact factor: 2.607

2.  Effect of Anti-IL-15 Administration on T Cell and NK Cell Homeostasis in Rhesus Macaques.

Authors:  Maren Q DeGottardi; Afam A Okoye; Mukta Vaidya; Aarthi Talla; Audrie L Konfe; Matthew D Reyes; Joseph A Clock; Derick M Duell; Alfred W Legasse; Amit Sabnis; Byung S Park; Michael K Axthelm; Jacob D Estes; Keith A Reiman; Rafick-Pierre Sekaly; Louis J Picker
Journal:  J Immunol       Date:  2016-07-18       Impact factor: 5.422

3.  Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis.

Authors:  Ljiljana Petrovic-Rackov; Nada Pejnovic
Journal:  Clin Rheumatol       Date:  2005-12-14       Impact factor: 2.980

4.  The distinct expressions of interleukin-15 and interleukin-15 receptor α in Behçet's disease.

Authors:  Jung-Yoon Choe; Hwajeong Lee; Sang Gyung Kim; Min Ji Kim; Sung-Hoon Park; Seong-Kyu Kim
Journal:  Rheumatol Int       Date:  2013-02-17       Impact factor: 2.631

5.  IL-15 concentrations in skeletal muscle and subcutaneous adipose tissue in lean and obese humans: local effects of IL-15 on adipose tissue lipolysis.

Authors:  Joseph R Pierce; Jill M Maples; Robert C Hickner
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-04-28       Impact factor: 4.310

Review 6.  Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications.

Authors:  Lili Magyari; Dalma Varszegi; Erzsebet Kovesdi; Patricia Sarlos; Bernadett Farago; Andras Javorhazy; Katalin Sumegi; Zsolt Banfai; Bela Melegh
Journal:  World J Orthop       Date:  2014-09-18

Review 7.  Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.

Authors:  Iain B McInnes; J Alastair Gracie
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

8.  The level of FoxO1 and IL-15 in skeletal muscle, serum and synovial fluid in people with knee osteoarthritis: a case control study.

Authors:  P Levinger; M K Caldow; J R Bartlett; J M Peake; C Smith; D Cameron-Smith; I Levinger
Journal:  Osteoporos Int       Date:  2016-01-13       Impact factor: 4.507

9.  Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.

Authors:  Elena Chertova; Cristina Bergamaschi; Oleg Chertov; Raymond Sowder; Jenifer Bear; James D Roser; Rachel K Beach; Jeffrey D Lifson; Barbara K Felber; George N Pavlakis
Journal:  J Biol Chem       Date:  2013-05-06       Impact factor: 5.157

10.  Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway.

Authors:  I González-Alvaro; A M Ortiz; C Domínguez-Jiménez; A Aragón-Bodi; B Díaz Sánchez; F Sánchez-Madrid
Journal:  Ann Rheum Dis       Date:  2008-10-28       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.